iShares US Healthcare

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///High Yield Bonds Appear Attractive
    Macroeconomic Analysis

    High Yield Offers Attractive Potential in a Yield-Starved World

    In an environment of generally decent, albeit recently disappointing, growth and gently rising yields, high yield offers attractive potential in a yield-starved world.

    By Russ Koesterich, CFA
  • uploads///part
    Company & Industry Overviews

    Danaher Corporation’s Excess Returns Fail to Impress

    Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.

    By Shannon Black
  • uploads///generic drug savings
    Company & Industry Overviews

    Will Generic Drugs Help Curb Healthcare Costs?

    Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///PE ratio
    Earnings Report

    Key Factors That Impact Johnson & Johnson’s Forward Valuation

    Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.

    By Nicole Sario
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///pipeline
    Company & Industry Overviews

    Pfizer Has Strong Track Record since 2010

    As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.

    By Jillian Dabney
  • uploads///The SP  Has Seen Multiple Expansion Since
    Macroeconomic Analysis

    Why US Stocks Appear Unattractive

    US stocks appear unattractive despite the recent correction. A stronger dollar (UUP) and a slowing world has negatively affected large-cap earnings.

    By Russ Koesterich, CFA
  • uploads///inorganic growth
    Company & Industry Overviews

    Four Key Deals: Analyzing Pfizer’s Impending Growth

    Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.

    By Jillian Dabney
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///lyrica
    Company & Industry Overviews

    Lyrica to Lose Patent Protection in the US in 2018

    After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.

    By Jillian Dabney
  • uploads///chart_ __ _cresemba
    Company & Industry Overviews

    Pfizer Has Received Commercial Rights for Cresemba in Europe

    On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.

    By Mike Benson
  • uploads///demographics
    Macroeconomic Analysis

    How Demographics Are Shaping Generic Drug Growth

    The generic drugs industry is likely to sustain robust growth in the coming years, and demographics are a key piece of the puzzle! In fact, demographics are shaping generic drug growth in a huge way.

    By VanEck
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///Sharpe Ratio Formula
    Healthcare

    Why you should use the Sharpe ratio when investing in the medical device industry

    What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]

    By Amritpal Khalsa
  • uploads///Chart
    Company & Industry Overviews

    Amgen’s Stock Performance and Estimates after Q3 2018

    Analysts expect Amgen’s (AMGN) stock price to fall ~1.4% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Assessing Pfizer’s Global Performance

    Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.

    By Mike Benson
  • uploads///Chart  Pfizer
    Company & Industry Overviews

    Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates

    Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes oncology products such as Alimta, Cyramza, Erbitux, Lartruvo, and Verzenio.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    Merck & Co.’s Human Vaccines Business in 3Q17

    Merck & Co.’s (MRK) Gardasil franchise reported a 22% decline in revenues to $675 million in 3Q17 compared to $860 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect

    Johnson & Johnson (JNJ), one of the largest pharmaceutical companies by revenue, is set to release its 4Q17 and 2017 earnings on January 23, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals Post-3Q17

    Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///
    Macroeconomic Analysis

    How the US Economy Performed in 2017

    This year has been a year to watch the US economy. Hopes for change, tax reform, and industry-friendly policies drove the markets (SPY) higher.

    By Ricky Cove
  • uploads///etf performance
    Company & Industry Overviews

    How the Medical Expense Tax Deduction Affects the Healthcare Industry

    According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.

    By Sarah Collins
  • uploads///Enbrel
    Company & Industry Overviews

    How Is Pfizer’s Immunology and Inflammation Portfolio Positioned Now?

    In 3Q17, Pfizer’s (PFE) Xeljanz generated revenues of $348 million, a ~48% increase on a year-over-year (or YoY) basis and 4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Behind Eli Lilly’s Cymbalta and Other Neuroscience Products in 3Q17

    Eli Lilly’s (LLY) neuroscience products portfolio includes the drugs Cymbalta, Strattera, and Zyprexa—all of which reported sales declines for 3Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Johnson & Johnson’s Profit Margins Trended in 3Q17

    Johnson & Johnson (JNJ) reported revenues of $19.7 billion during 3Q17, a 10.3% increase as compared to revenues of $17.8 billion during 3Q16. However, the gross profit margins contracted in 3Q17.

    By Mike Benson
  • uploads///Chart  AMGN
    Healthcare

    Amgen Stock: Performance in 3Q17

    Amgen stock has risen ~8.2% in 3Q17. It has risen ~25.9% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Understanding Merck’s Valuation after 2Q17

    Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Eli Lilly’s Oncology Products in 2Q17

    Alimta’s sales totaled $532.9 million during 2Q17, a 12.0% decrease compared to $607.1 million for 2Q16.

    By Mike Benson
  • uploads///Chart  Vir
    Company & Industry Overviews

    Bristol-Myers Squibb’s Virology Products in 2Q17

    Bristol-Myers Squibb’s (BMY) virology products portfolio includes products for the treatment of chronic virus infections.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Revenue Continues to Grow in 2Q17

    Johnson & Johnson’s revenue Johnson & Johnson (JNJ) reported ~2% growth in its top line to $18.8 billion in 2Q17, compared with $18.5 billion in 2Q16. The company surpassed analysts’ EPS (earnings-per-share) estimate of of $1.80 with EPS of $1.83. The above chart shows Johnson & Johnson’s revenue over the last few quarters. As the company […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte Had These Key Collaborations and Developments in 2Q17

    Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    How Allergan’s Segments Contributed to Overall Revenues

    The US Specialized therapeutics business includes products from various therapeutic areas including eye care, medical aesthetics including skin care, facial aesthetics, plastic surgery and other products, medical dermatology, and neuroscience and urology franchises.

    By Mike Benson
  • uploads///Chart  PGC
    Company & Industry Overviews

    Pfizer’s Major Growth Drivers in 2Q17

    Pfizer’s (PFE) growth contributors include products from both the innovative health and essential health businesses.

    By Mike Benson
  • uploads///Chart  Orencia
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Orencia and Other Brands

    Bristol-Myers Squibb’s (BMY) immunoscience business is represented by the drug Orencia. Let’s take a look at Orencia’s revenue over the last few quarters.

    By Mike Benson
  • uploads///Chart  Cardio
    Earnings Report

    Eli Lilly in 2Q17: Performance of Cardiovascular Products

    Cialis reported nearly flat revenues at $627.3 million in 2Q17 compared to $630.5 million for 2Q16.

    By Mike Benson
  • uploads///GE Healthcare
    Earnings Report

    What Led the Rise in GE’s Healthcare Revenue in 2Q17?

    GE’s Healthcare segment remained a top performer in 2Q17. Revenue-wise, this segment remained the third-largest contributor to GE’s total operating revenue of $28.0 billion.

    By Samuel Prince
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts’ Recommendations for Merck in July 2017

    Twenty-two analysts covered Merck in July 2017. Four analysts recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Chart  Growth
    Earnings Report

    What Drove Johnson & Johnson’s Growth in 2Q17

    Johnson & Johnson’s growth rate As discussed earlier, Johnson & Johnson (JNJ) reported an increase of ~2.9% in revenue to $18.8 billion in 2Q17, compared with $18.5 billion in 2Q16. The above graph compares the growth rate and impact of foreign exchange on Johnson & Johnson’s total revenue over the last few quarters. Foreign exchange […]

    By Mike Benson
  • uploads///Chart  USST
    Company & Industry Overviews

    How Allergan’s US Specialized Therapeutics Segment Performed

    Allergan’s (AGN) US Specialized Therapeutics segment includes branded products from a range of therapeutic areas.

    By Mike Benson
  • uploads///Chart  Rev
    Earnings Report

    Johnson & Johnson’s 2Q17 Revenue Estimates: Expect Growth!

    Analysts expect a rise of 2.6% in Johnson & Johnson’s 2Q17 revenue. This growth is expected to be driven by the strong performances of some of JNJ’s key products.

    By Mike Benson
  • uploads///Chart  JNJ
    Company & Industry Overviews

    How Johnson & Johnson Has Performed in 2Q17

    A look at Johnson & Johnson Johnson & Johnson (JNJ) is one of the largest pharmaceutical and healthcare companies. With headquarters in New Brunswick, New Jersey, the company sells its products in over 200 countries worldwide. Stock price performance Johnson & Johnson’s stock price has risen ~5.9% in 2Q17. As of July 7, 2017, its stock […]

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Merck’s Valuation on June 28, 2017

    Of the 22 analysts covering Merck, 14 analysts recommended a “buy”, seven analysts recommended a “hold,” and one analyst recommended a “sell.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Incyte’s Product Portfolio Look in 1Q17?

    Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Ionis Phamaceuticals’ Revenue Stream in 1Q17

    Ionis Phamaceuticals’ revenue Ionis Pharmaceuticals (IONS) reported revenue of $110.3 million in 1Q17, 200% higher than its revenue of $36.9 million in 1Q16. Analysts estimate that its revenue will increase by over 100% to $78.9 million in 2Q17, mainly driven by growth in research and development revenue. Revenue performance The above graph shows Ionis’s revenue over the […]

    By Mike Benson
  • uploads///Rising Contribution in Private Health Insurance
    Macroeconomic Analysis

    Rising Costs Are a Major Issue in the Healthcare Sector

    The US economy is dealing with rising healthcare costs. The national healthcare expenditure grew 5.8% to $3.2 trillion in 2015 or $9,990 per person.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Segmental Performance in 1Q17

    Merck’s Pharmaceutical segment contributed nearly 86.7% of the company’s total revenues in 1Q17 compared to 87.0% in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind BMY’s Cardiovascular Performance in 1Q17

    Eliquis is a new blockbuster drug in Bristol-Myers Squibb’s portfolio, and its sales rose ~50% to $1.1 billion in 1Q17.

    By Mike Benson
  • uploads///Chart  USGM
    Earnings Report

    Behind Allergan’s US General Medicines Segment in 1Q17

    In 1Q17, revenues from Allergan’s US General Medicine segment fell 7.4% to $1.35 billion, as compared to $1.45 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Ratings
    Miscellaneous

    Analysts’ Ratings and Recommendations for Pfizer

    Wall Street analysts expect Pfizer’s (PFE) top line to rise 0.6% to ~$13.1 billion in 1Q17. Its earnings per share are expected to be $0.67 in the quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Merck’s 1Q17 Estimates: Revenues Will Likely Decrease

    For 1Q17, analysts expect Merck and Co.’s (MRK) revenues to be ~$9.25 billion—nearly a 0.7% decrease compared to revenues of $9.31 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  NewProducts
    Earnings Report

    Will New Products Help Eli Lilly in 1Q17?

    Eli Lilly (LLY) has launched various products, including Portrazza, Cyramza, Basaglar, Jardiance, and Trulicity.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Johnson & Johnson’s 1Q17 Earnings Miss Revenue Estimates

    Johnson & Johnson released its 1Q17 earnings on April 18, 2017, reporting a ~1.6% rise in its top line in 1Q17 compared to 1Q16.

    By Mike Benson
  • uploads///Chart  BMY
    Miscellaneous

    How Bristol-Myers Squibb Stock Performed in 1Q17

    Bristol-Myers Squibb’s stock price fell ~11.7% in 1Q17. On April 6, 2017, the stock’s price had risen 9.2% year-to-date (or YTD).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Wall Street Analysts Recommend for Pfizer

    The strong performance of innovative products and the inclusion of the Hospira business have driven Pfizer’s (PFE) 2016 earnings.

    By Mike Benson
  • uploads///Enbrels challenges
    Company & Industry Overviews

    The Competitive Landscape for Enbrel

    Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Falling Revenue in Allergan’s US General Medicines Segment

    During 3Q16, the revenues for the US General Medicine segment fell 4.1% to $1.49 billion—compared to $1.55 billion in 3Q15.

    By Mike Benson
  • uploads///I O developemnt
    Company & Industry Overviews

    Bristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market

    With Bristol-Myers Squibb’s (BMY) Opdivo being the standard of care in the second-line lung cancer space, it faces cutthroat competition from Merck’s (MRK) Keytruda.

    By Jillian Dabney
  • uploads/// Sh yield Index
    Macroeconomic Analysis

    Shareholder Buyback: A Powerful Tool to Achieve Higher Income

    What products single out specifically the share buyback companies?

    By Peter Barnes
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Launched Zinbryta in the US in August

    On May 27, 2016, AbbVie and Biogen’s Zinbryta was approved by the FDA as a therapy for adults suffering from relapsing forms of MS (multiple sclerosis).

    By Margaret Patrick
  • uploads///Chart  Revenues
    Earnings Report

    Is Eli Lilly Rebounding from Patent Expiry of Cymbalta?

    Eli Lilly (LLY) reported a growth of ~8.6% in revenues for 2Q16 over 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Allergan Acquired Topokine Therapeutics?

    Allergan (AGN) announced the acquisition of Topokine Therapeutics, a biotechnology company that develops fat-reducing medicines, in April 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Could Happen with AbbVie’s EFNA4-Calicheamicin in Cancer Stem-Cell Therapy?

    Based preclinical trials and its phase-1 trial, AbbVie expects its EFNA4-Calicheamicin therapy, PF-06647263, to become a strong option for ovarian cancer.

    By Margaret Patrick
  • uploads///ANAC PFE downside
    Miscellaneous

    Pfizer Purchases Anacor in a $5.2 Billion Cash Deal

    On May 16, 2016, Pfizer (PFE) announced that it was acquiring dermatology pharma company Anacor (ANAC) in a transaction valued at $5.2 billion.

    By Brent Nyitray, CFA, MBA
  • uploads///business strategy
    Company & Industry Overviews

    The Business Strategies Driving Boston Scientific’s Growth

    Boston Scientific registered emerging market sales growth of approximately 13% in 2015, representing a steady growth in international markets.

    By Sarah Collins
  • uploads/// App Economy
    Macroeconomic Analysis

    What’s behind the US Economy’s Remarkable Labor Market Strength?

    The US labor market has shown tremendous resilience amid concerns over various issues, like aging demographics.

    By Rick Rieder
  • uploads///Chart
    Earnings Report

    Pfizer’s Pipeline and Corporate Developments in 2016

    Pfizer announced the termination of the merger agreement with Allergan (AGN) in April 2016. The company paid $150 million to Allergan toward expenses for the transaction.

    By Mike Benson
  • uploads///profitability
    Earnings Report

    Baxter’s 1Q16 Profitability and 2016 Guidance

    Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Merck’s Valuation Cheat Sheet for 1Q16

    Forward PE and EV-to-EBITDA multiples are two of the best valuation multiples to use when valuing Merck, given its relatively stable and visible earnings.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Will Merck & Co.’s Revenue Recover Growth in 1Q16?

    Analysts expect Merck and Co.’s (MRK) revenue for 1Q16 to be around $9.44 billion, nearly 0.2% higher than the $9.42 billion in revenue it reported in 1Q15.

    By Mike Benson
  • uploads///nutrition operatinng margin
    Company & Industry Overviews

    Why Abbott Laboratories Is a Leader in Nutritional Products

    Abbott Laboratories’ Nutritional Products segment is the company’s leading segment, growing at a fast pace, with rapidly increasing margins and revenues.

    By Sarah Collins
  • uploads///VALUATION
    Company & Industry Overviews

    Analyzing Medtronic’s Valuations Compared to Its Peers

    On March 30, 2016, Medtronic (MDT) was trading at a forward PE (price-to-earnings) ratio of ~15.9x—compared to the industry average of 19.8x.

    By Sarah Collins
  • uploads///strategic initiatives
    Company & Industry Overviews

    Strategic Initiatives Driving Baxter’s Margin Expansion Goal

    Baxter witnessed a series of changes in 2015, including a change in management, operational structure, and the establishment of a new strategic framework.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Expected Profitability in 1Q16

    Johnson & Johnson has restructured its business over the past few years and has divested some of its low profitability products.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Did Amgen Implement Multi-Pronged Strategy for Repatha?

    Amgen (AMGN) is expecting to strengthen Repatha’s brand position in the global cardiovascular market in 2016 through a multi-pronged strategy.

    By Margaret Patrick
  • uploads///forward pe
    Company & Industry Overviews

    How Do Johnson & Johnson’s Valuations Compare to Peers?

    On March 17, 2016, Johnson & Johnson (JNJ) was trading at a forward PE (price-to-earnings) multiple of ~16.5x compared to the industry average of ~19.6x.

    By Sarah Collins
  • uploads///Return Dispersion Within Asset Classes Has Been Dramatic
    Macroeconomic Analysis

    Why Returns Will Likely Be Far from Uniform within Asset Classes

    During the last few years, return dispersions within asset classes have been dramatic.

    By Rick Rieder
  • uploads///Graph
    Earnings Report

    AbbVie’s Net Profit Margin Expected to Reach 29.8% in 4Q15

    AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%.

    By Margaret Patrick
  • uploads///analytical instruments segmentation
    Company & Industry Overviews

    Thermo Fisher Scientific’s Analytical Instruments Business Segment

    Thermo Fisher Scientific’s Analytical Instruments segment earned revenues of ~$3.3 billion in 2014, representing organic growth of around 4%.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Sizing up Abbott Laboratories’ Medical Device Segment

    Abbott’s Medical Device segment accounts for 27% of the company’s total sales. Its Vascular sub-segment generates 50% of the segment’s revenue.

    By Sarah Collins
  • uploads///ardiovascular segmentation
    Company & Industry Overviews

    Evaluating Medtronic’s Cardiac and Vascular Devices Segment

    Medtronic’s Cardiac and Vascular segment consists of Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular.

    By Sarah Collins
  • uploads///Earnings Growth Follows the Trajectory of GDP
    Macroeconomic Analysis

    What’s the Biggest Driver of Earnings Growth?

    Economic growth is the biggest driver of earnings growth. Earnings growth seems to follow the same trajectory of GDP growth.

    By Russ Koesterich, CFA
  • uploads///jnj pe
    Earnings Report

    How Did Johnson & Johnson Perform Compared to Its Peers?

    The peers outperformed Johnson & Johnson based on the net profit margin. The ETFs outperformed it based on the price movement, PE ratio, and PBV ratio.

    By Gabriel Kane
  • uploads///Graph
    Miscellaneous

    Synergies in Centene’s Acquisition of Health Net

    Centene projects that Health Net’s acquisition will help Centene realize pre-tax synergies worth $150 million by the end of the second year after the closure of the deal.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Analyzing the Market’s Response to the Centene–Health Net Deal

    The Centene–Health Net deal is expected to be completed by early 2016, pending approval by the shareholders of both companies.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Centene–Health Net Entity Could Be Medicaid Leader

    Centene aims to position itself as a leader in the fast-growing Medicaid market. Health Net’s acquisition will add ~1.7 million Medicaid members to the company’s portfolio.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Centene Announces Its Acquisition of Health Net

    On July 2, Centene announced the acquisition of Health Net for a combination of cash and shares amounting to $6.8 billion. This includes the assumption of Health Net’s $500 million debt.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    GlaxoSmithKline’s Associated Business Segments

    The key business segment of GlaxoSmithKline’s operations is Pharmaceuticals, followed by Consumer Healthcare and Vaccines.

    By Mike Benson
  • uploads///Biotech Stocks Have Witnessed a Tremendous Growth in Earnings
    Macroeconomic Analysis

    Healthcare Stocks Likely to Outperform despite Rate Hike

    Even though healthcare stocks (IYH) are usually considered defensive in nature, they traditionally hold up well in the run-up to a rate hike.

    By Russ Koesterich, CFA
  • uploads///Margins
    Earnings Report

    Why Teva’s Generic Medicines Profitability Improved in 1Q15

    Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.

    By Nicole Sario
  • uploads///Revenues
    Earnings Report

    Why Teva’s 1Q15 Revenues Declined Marginally

    In 1Q15, Teva beat Wall Street analysts’ revenue estimates of $4.81 billion, posting revenues of $4.98 million, an increase of ~3.5%.

    By Nicole Sario
  • uploads///Cash Reserve
    Earnings Report

    Does Johnson & Johnson Have a Plan for Huge Cash Reserve?

    Johnson & Johnson (JNJ) has a huge cash reserve amounting to ~$15 billion in 4Q14. The company might use the cash for merger and acquisition (or M&A).

    By Nicole Sario
  • uploads///Young population low
    Macroeconomic Analysis

    The Cyclical Aspect of the Labor Market Conundrum

    There is a cyclical aspect of the labor market conundrum. People typically drop out of the work force during and immediately after recessions.

    By Russ Koesterich, CFA
  • uploads///PRGO_Rx to OTC
    Miscellaneous

    Mylan–Perrigo Merger: Expanding into Over-the-Counter Drugs

    Pharmaceutical company Mylan’s (MYL) intention to acquire Perrigo became public on April 6, 2015. The acquisition would permit Mylan to expand into the over-the-counter drugs segment.

    By Nicole Sario
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.